When stratified by PAM50 subtype, the overall survival was markedly worse in the patients with HER2-enriched or Basal-like breast cancer than those with Luminal A or B breast cancer (P for interaction = 0.016), while this phenomenon did not occur for recurrence-free survival. This evidence concerns the gene ERBB2 and breast carcinoma.